Posted by Michael Wonder on 18 Jun 2018
ICER to assess canakinumab for atherosclerosis
18 June 2018 - Review will be subject of January Midwest CEPAC meeting; open Input now being accepted until 5 July.
The Institute for Clinical and Economic Review (ICER) today announced plans to develop a report assessing the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis. The report is set to be reviewed during a January 2019 public meeting of the Midwest Comparative Effectiveness Public Advisory Council, one of ICER's three independent evidence appraisal committees.
Canakinumab was originally approved by the FDA in 2009 and is marketed for various rare inflammatory disorders; it is currently under FDA review for a new indication in atherosclerosis.
